TD Today: Gaps in Recognition & Impact

This infographic, titled "TD Today: Gaps in Recognition & Impact," highlights the disconnect between advances in tardive dyskinesia (TD) care and how often it still goes unrecognized in practice. It presents key stats — TD affects roughly 1 in 4 antipsychotic-treated patients, can be irreversible even after stopping the causative medication, and remains undiagnosed in an estimated 65% of US cases — alongside the reasons TD gets missed, from clinician training gaps to patients minimizing their own symptoms. It also emphasizes the real-world toll on patients (speech, eating, social confidence, work, emotional well-being) beyond what a standard movement exam captures. Finally, it outlines how both assessment (newer patient-reported tools like Impact-TD and TDIS) and treatment (VMAT2 inhibitors with expanded formulations) are evolving, closing with three practical steps clinicians can take at a patient's next visit.